Welcome to our dedicated page for Aktis Oncology SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aktis Oncology, Inc. filings document the company’s transition into a Nasdaq-listed public oncology issuer and its disclosure obligations as a clinical-stage oncology company. S-1/A registration materials and current reports describe its targeted radiopharmaceutical pipeline, including AKY-1189 and AKY-2519, the miniprotein radioconjugate platform, collaboration revenue, and operating results.
Its filings also cover post-IPO governance and capital-structure matters, including amended charter provisions, authorized common, Class A common and undesignated preferred stock, classified board provisions, director appointments, board committee structure, financial-results exhibits, and registered common stock under the AKTS symbol.
Aktis Oncology, Inc. reported Q2 2026 as an early-stage, clinical oncology company investing heavily in its radiopharmaceutical pipeline. Collaboration revenue from its Eli Lilly agreement rose to $3.4 million for the quarter and $6.6 million year-to-date. Operating expenses expanded, with Q2 research and development at $25.3 million and general and administrative at $7.0 million, driving a quarterly net loss of $24.1 million and a six‑month loss of $42.5 million. Following a January 2026 IPO and conversion of preferred stock, the balance sheet strengthened: cash, cash equivalents, and marketable securities totaled $517.3 million, and stockholders’ equity reached $484.8 million as of June 30, 2026. Management believes this liquidity will fund operations into 2029, while it advances lead candidates [225Ac]Ac‑AKY‑1189 and [225Ac]Ac‑AKY‑2519 through clinical development.
Aktis Oncology, Inc. reported second quarter 2026 results and outlined progress across its targeted radiopharmaceutical pipeline. The company highlighted first-in-human imaging and dosimetry data for AKY-2519 showing robust tumor uptake and limited normal tissue exposure, and continued enrollment in a Phase 1b trial of AKY-1189 in urothelial and other Nectin-4 expressing tumors. Aktis initiated a Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer and cleared regulatory review for a Phase 1b basket trial in other B7-H3 expressing tumors, both expected to yield preliminary data in 2027. An in-house GMP facility is expected to be operational in the second half of 2026 to support clinical supply. Cash, cash equivalents, and marketable securities were $517.3 million as of June 30, 2026, expected to fund operations into 2029. For the quarter, collaboration revenue was $3.4 million, research and development expenses $25.3 million, general and administrative expenses $7.0 million, and net loss $24.1 million.
Aktis Oncology director Ken Herrmann exercised vested stock options and sold the resulting shares on July 20, 2026. He exercised options for 3,506 shares at $0.08 per share and 1,350 shares at $1.91 per share, acquiring 4,856 common shares. He then sold 4,856 common shares at a weighted average price of $24.5622 per share in transactions priced between $24.50 and $24.66.
Aktis Oncology, Inc. director Ken Herrmann reported a same-day option exercise and sale. He exercised 3,065 stock options at $0.0800 per share into 3,065 shares of common stock, then sold 3,065 shares at a weighted average price of $25.2067, with individual trades between $25.00 and $25.4950. The exercised options were fully vested, and 3,506 options from this award remained outstanding, expiring November 23, 2030.
Akoustis Technologies, Inc. (AKTS) has a notice of proposed sale of common stock by an affiliate. A brokerage account at Morgan Stanley Smith Barney LLC Executive Financial Services is listed for the planned sale of 4,856 shares of common stock on July 20, 2026 on NASDAQ.
The shares are indicated as coming from a stock option exercise, with a stated market value of $119,274.53. The filing also notes that on July 17, 2026, Ken Herrmann sold 3,065 shares of common stock over the prior three months for $77,258.54 in aggregate.
Aktis Oncology, Inc. executive Shulamit Ron-Bigger, Chief Operating Officer, reported an exercise-and-sale transaction in company equity. On July 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $3.66 per share and on the same date sold 50,000 shares of common stock in multiple open-market transactions at weighted average prices around the high-$20s per share. After these transactions, she continued to hold 217,888 stock options expiring in 2032.
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere reported an exercise-and-sell transaction in Common Stock on July 8, 2026. He exercised stock options to acquire 50,000 shares at $4.95 per share, then sold 50,000 shares in multiple open-market sales at weighted average prices around the high-$20s range, leaving no Common Stock held directly and 221,218 stock options outstanding with a $4.95 exercise price expiring on June 30, 2034.